Table 4. Differences between VTE vs. no VTE in demographic data, clinical data, comorbidities and outcome.

parameter	VTE group (n = 14)	no VTE group (n = 36)	p-value
age	60.5(SD 9.7)	76.1(SD 94.5)	0.543
gender
male	10 (30%)	23 (70%)
female	4 (25%)	12 (75%)	0.700
symptoms
fever*
No	4 (50%)	4 (50%)
Yes	8 (22%)	29 (78%)	0.100
cough*
no	2 (20%)	8 (80%)
yes	9 (26%)	25 (74%)	0.678
dyspnoea*
no	4 (40%)	6 (60%)
yes	10 (29%)	24 (71%)	0.527
fatigue*
no	6 (46%)	7 (54%)
yes	6 (26%)	17 (74%)	0.220
gastrointestinal*
no	10 (45%)	12 (55%)
yes	2 (15%)	11 (85%)	0.070
taste dysfunction*
no	12 (44%)	15 (56%)
yes	0 (0%)	8 (100%)	0.020
comorbidities
diabetes*
no	10 (25%)	30 (75%)
yes	4 (40%)	6 (60%)	0.345
cardiac failure*
no	14 (29%)	34 (71%)
yes	0 (0%)	2 (100%)	0.368
coronary heart disease*
no	14 (30%)	32 (70%)
yes	0 (0%)	4 (100%)	0.193
COPD*
no	14 (29%)	34 (71%)
yes	0 (0%)	2 (100%)	0.368
asthma*
no	14 (30%)	33 (70%)
yes	0 (0%)	3 (100%)	0.265
high blood pressure*
no	9 (30%)	21 (70%)
yes	5 (25%)	15 (75%)	0.700
outcome
negative	13 (92.9%)	22 (61.1%)
positive	1 (7.1%)	14 (38.9%)	0.028
time between symptom onset and CT scan (days)	16 (IQR 13.5–20)	15 (IQR 7–25)	0.326**
0–10	1 (8%)	12 (92%)	reference
11–20	6 (46%)	7 (54%)	0.027
21–30	2 (29%)	5 (71%)	0.212
> 30	1 (17%)	5 (83%)	0.554

COPD = chronic obstructive pulmonary disease, SD = standard deviation, VTE = venous thromboembolism

Positive outcome: treatment on regular ward, or discharge

Negative outcome: treatment on ICU, mechanical ventilation, ECMO, or death

* occasional missing values

** for 11 patients symptom onset was not documented